

5. (Once amended) The method of claim 1 [any one of the preceding claims] wherein the growth factor is expressed as a fusion with a viral envelope protein and is attached to the N-terminus of a retroviral envelope protein.

6. (Once amended) The method of claim 5 [any one of the preceding claims] wherein the growth factor is expressed as a fusion with a viral envelope protein and is fused to the envelope protein via a cleavable linker.

7. (Once amended) The method of claim 1 [any one of the preceding claims] wherein the envelope protein is viral envelope SU protein.

8. (Once amended) The method of claim 1 [any one of the preceding claims] wherein the retroviral packaging cell line further expresses nucleic acid encoding a receptor to target the cells to the bone marrow and/or an immunosuppressive factor so that the receptor and/or immunosuppressive factor are displayed on the cell surface.

9. (Once amended) A population of cells produced by the method of claim 1 [any one of claims 1 to 8] having the nucleic acid encoding a polypeptide for treating a disease or disorder stably incorporated into their genome.

11. (Once amended) A method of treating a patient comprising administering to the patient an effective amount of the [Use of the] cells of claim 9 [in the preparation of a medicament for the treatment of a disease or disorder in a patient that responds to the polypeptide].

12. (Once amended) The method [use] of claim 11 wherein the cells are administered by implantation into the patient.

15. (Once amended) The retroviral packaging cell line of claim 13 [or claim 14] wherein the growth factor is stem cell factor (SCF) or FLT3 ligand.

16. (Once amended) The retroviral packaging cell line of claim 13 [any one of claims 13 to 16] wherein the cell line displays multiple growth factors.

Art cont.

17. (Once amended) The retroviral packaging cell line of claim 13 [any one of claims 13 to 16] wherein the cell line is a lentiviral packaging cell line.

18. (Once amended) The retroviral packaging cell line of claim 13 which further expresses [any one of the claims 13 to 17, further expressing] nucleic acid encoding a receptor to target the cells to the bone marrow and/or an immunosuppressive factor so that the receptor and/or immunosuppressive factor are displayed on the cell surface.

19. (Once amended) A pharmaceutical composition comprising the retroviral packaging cell line of claim 13 [any one of claims 13 to 18], in combination with a pharmaceutically acceptable carrier.

20. (Once amended) A method of treating a patient comprising administering to the patient an effective amount of [Use of] the retroviral packaging cell line of claim 13 [claims 13 to 18 in the preparation of a medicament for treating a disease or disorder that responds to the polypeptide].

21. (Once amended) The method [use] of claim 20 wherein the retroviral packaging cell line is administered by implantation into a patient's bone marrow or by infusion into a patient's blood.

///

///

///

///

///

///

///

///

///